The FGF metabolic axis

Abstract

Members of the fibroblast growth factor (FGF) family play pleiotropic roles in cellular and metabolic homeostasis. During evolution, the ancestor FGF expands into multiple members by acquiring divergent structural elements that enable functional divergence and specification. Heparan sulfate-binding FGFs, which play critical roles in embryonic development and adult tissue remodeling homeostasis, adapt to an autocrine/paracrine mode of action to promote cell proliferation and population growth. By contrast, FGF19, 21, and 23 coevolve through losing binding affinity for extracellular matrix heparan sulfate while acquiring affinity for transmembrane α-Klotho (KL) or β-KL as a coreceptor, thereby adapting to an endocrine mode of action to drive interorgan crosstalk that regulates a broad spectrum of metabolic homeostasis. FGF19 metabolic axis from the ileum to liver negatively controls diurnal bile acid biosynthesis. FGF21 metabolic axes play multifaceted roles in controlling the homeostasis of lipid, glucose, and energy metabolism. FGF23 axes from the bone to kidney and parathyroid regulate metabolic homeostasis of phosphate, calcium, vitamin D, and parathyroid hormone that are important for bone health and systemic mineral balance. The significant divergence in structural elements and multiple functional specifications of FGF19, 21, and 23 in cellular and organismal metabolism instead of cell proliferation and growth sufficiently necessitate a new unified and specific term for these three endocrine FGFs. Thus, the term "FGF Metabolic Axis," which distinguishes the unique pathways and functions of endocrine FGFs from other autocrine/paracrine mitogenic FGFs, is coined.

References 188

1. 1.

   Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235-253.

   Not in our library10.1038/nrd2792

2. 2.

   Luo Y, Ye S, Li X, Lu W. Emerging structure-function paradigm of endocrine FGFs in metabolic diseases. Trends Pharmacol Sci. 2019;40(2):142-153.

   Not in our library10.1016/j.tips.2018.12.002

3. 3.

   Li X, Wang C, Xiao J, McKeehan WL, Wang F. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol. 2016;53:155-167.

   Not in our library10.1016/j.semcdb.2015.12.014

4. 4.

   Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci USA. 1991;88(8):3441-3445.

   Not in our library10.1073/pnas.88.8.3441

5. 5.

   Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, Moe OW, Liang G, Li X, Mohammadi M. αKlotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018;553(7689):461-466.

   Not in our library10.1038/nature25451

6. 6.

   Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15(1):51-69.

   Not in our library10.1038/nrd.2015.9

7. 7.

   Luo Y, Ye S, Chen X, Gong F, Lu W, Li X. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine Growth Factor Rev. 2017;38:59-65.

   Not in our library10.1016/j.cytogfr.2017.08.001

8. 8.

   McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998;59:135-176.

   Not in our library10.1016/s0079-6603(08)61031-4

9. 9.

   Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563-569.

   Not in our library10.1016/j.tig.2004.08.007

10. 10.

    Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149(2):121-130.

    Not in our library10.1093/jb/mvq121

11. 11.

    Luo Y, Lu W, Li X. Unraveling endocrine FGF signaling complex to combat metabolic diseases. Trends Biochem Sci. 2018;43(8):563-566.

    Not in our library10.1016/j.tibs.2018.05.001

12. 12.

    Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281(23):15694-15700.

    Not in our library10.1074/jbc.m601252200

13. 13.

    Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci USA. 1973;70(9):2702-2706.

    Not in our library10.1073/pnas.70.9.2702

14. 14.

    Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 1974;249(453):123-127.

    Not in our library10.1038/249123a0

15. 15.

    Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58(1):575-606.

    Not in our library10.1146/annurev.bi.58.070189.003043

16. 16.

    Luo Y, Ye S, Kan M, McKeehan WL. Control of fibroblast growth factor (FGF) 7- and FGF1-induced mitogenesis and downstream signaling by distinct heparin octasaccharide motifs. J Biol Chem. 2006;281(30):21052-21061.

    Not in our library10.1074/jbc.m601559200

17. 17.

    Gospodarowicz D, Ill CR, Hornsby PJ, Gill GN. Control of bovine adrenal cortical cell proliferation by fibroblast growth factor. Lack of effect of epidermal growth factor. Endocrinology. 1977;100(4):1080-1089.

    Not in our library10.1210/endo-100-4-1080

18. 18.

    Mansour SL, Goddard JM, Capecchi MR. Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear. Development. 1993;117(1):13-28.

    Not in our library10.1242/dev.117.1.13

19. 19.

    Guo C, Sun Y, Zhou B, Adam RM, Li X, Pu WT, Morrow BE, Moon A, Li X. A Tbx1-Six1/Eya1-Fgf8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. J Clin Invest. 2011;121(4):1585-1595.

    Not in our library10.1172/jci44630

20. 20.

    Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29(14):1463-1486.

    Not in our library10.1101/gad.266551.115

21. 21.

    Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science. 1993;259(5103):1918-1921.

    Not in our library10.1126/science.8456318

22. 22.

    Ye S, Luo Y, Lu W, Jones RB, Linhardt RJ, Capila I, Toida T, Kan M, Pelletier H, McKeehan WL. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry. 2001;40(48):14429-14439.

    Not in our library10.1021/bi011000u

23. 23.

    Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013;14(3):166-180.

    Not in our library10.1038/nrm3528

24. 24.

    Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997;89(5):693-702.

    Not in our library10.1016/s0092-8674(00)80252-4

25. 25.

    Huang Z, Marsiglia WM, Basu R U, Rahimi N, Ilghari D, Wang H, Chen H, Gai W, Blais S, Neubert TA, Mansukhani A, Traaseth NJ, Li X, Mohammadi M. Two FGF receptor kinase molecules act in concert to recruit and transphosphorylate phospholipase Cγ. Mol Cell. 2016;61(1):98-110.

    Not in our library10.1016/j.molcel.2015.11.010

26. 26.

    Dorey K, Amaya E. FGF signalling: diverse roles during early vertebrate embryogenesis. Development. 2010;137(22):3731-3742.

    Not in our library10.1242/dev.037689

27. 27.

    Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999;274(18):12827-12834.

    Not in our library10.1074/jbc.274.18.12827

28. 28.

    Jin C, Wang F, Wu X, Yu C, Luo Y, McKeehan WL. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res. 2004;64(13):4555-4562.

    Not in our library10.1158/0008-5472.can-03-3752

29. 29.

    Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 2015;25(4):221-233.

    Not in our library10.1016/j.tcb.2014.11.003

30. 30.

    Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, Perales MA. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013;48(1):99-104.

    Not in our library10.1038/bmt.2012.115

31. 31.

    Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19(5):461-468.

    Not in our library10.1684/ejd.2009.0750

32. 32.

    Akita S, Akino K, Imaizumi T, Hirano A. Basic fibroblast growth factor accelerates and improves second-degree burn wound healing. Wound Repair Regen. 2008;16(5):635-641.

    Not in our library10.1111/j.1524-475x.2008.00414.x

33. 33.

    Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, Sheng Z. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet. 1998;352(9141):1661-1664.

    Not in our library10.1016/s0140-6736(98)01260-4

34. 34.

    Maddaluno L, Urwyler C, Werner S. Fibroblast growth factors: key players in regeneration and tissue repair. Development. 2017;144(22):4047-4060.

    Not in our library10.1242/dev.152587

35. 35.

    Zhao YZ, Zhang M, Wong HL, Tian XQ, Zheng L, Yu XC, Tian FR, Mao KL, Fan ZL, Chen PP, Li XK, Lu CT. Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGFloaded nanoparticles and ultrasound-targeted microbubble destruction technique. J Control Release. 2016;223:11-21.

    Not in our library10.1016/j.jconrel.2015.12.030

36. 36.

    Liang G, Song L, Chen Z, Qian Y, Xie J, Zhao L, Lin Q, Zhu G, Tan Y, Li X, Mohammadi M, Huang Z. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int. 2018;93(1):95-109.

    Not in our library10.1016/j.kint.2017.05.013

37. 37.

    Li R, Li Y Y, Zhao Y, Chen H, Yuan Y, Xu K, Zhang H, Lu Y, Wang J, Li X, Jia X, Xiao J. Heparin-poloxamer thermosensitive hydrogel loaded with bFGF and NGF enhances peripheral nerve regeneration in diabetic rats. Biomaterials. 2018;168:24-37.

    Not in our library10.1016/j.biomaterials.2018.03.044

38. 38.

    Wu J, Zhu J, He C, Xiao Z, Ye J, Li Y, Chen A, Zhang H, Li X, Lin L, Zhao Y, Zheng J, Xiao J. Comparative study of heparinpoloxamer hydrogel modified bFGF and aFGF for in vivo wound healing efficiency. ACS Appl Mater Interfaces. 2016;8(29):18710-18721.

    Not in our library10.1021/acsami.6b06047

39. 39.

    Wu J, Ye J, Zhu J, Xiao Z, He C, Shi H, Wang Y, Lin C, Zhang H, Zhao Y, Fu X, Chen H, Li X, Li L, Zheng J, Xiao J. Heparin-based coacervate of FGF2 improves dermal regeneration by asserting a synergistic role with cell proliferation and endogenous facilitated VEGF for cutaneous wound healing. Biomacromolecules. 2016;17(6):2168-2177.

    Not in our library10.1021/acs.biomac.6b00398

40. 40.

    Wang Q, He Y, Zhao Y, Xie H, Lin Q, He Z, Wang X, Li J, Zhang H, Wang C, Gong F, Li X, Xu H, Ye Q, Xiao J. A thermosensitive heparin-poloxamer hydrogel bridges aFGF to treat spinal cord injury. ACS Appl Mater Interfaces. 2017;9(8):6725-6745.

    Not in our library10.1021/acsami.6b13155

Cited by papers we hold 5

• Application of neurotrophic and proangiogenic factors as therapy after peripheral nervous system injury · 2022
  Not checked
• Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations · 2022
  No notice
• Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer · 2021
  Not checked
• An in situ tissue engineering scaffold with growth factors combining angiogenesis and osteoimmunomodulatory functions for advanced periodontal bone regeneration · 2021
  No notice
• FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.